Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860298 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL31430795 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL27575950 | 0.88 | CA12 (0.52) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL2371182 | 0.88 | LCK (0.48) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL28799490 | 0.87 | KEAP1 (0.46) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL590353 | 0.84 | AKR1C4 (0.47) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL29851193 | 0.84 | AKR1C4 (0.47) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL1512601 | 0.83 | CA12 (0.47) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL15719837 | 0.83 | LCK (0.48) | SMN1; SMN2LCKFYNCA12CA1 | |
| SCHEMBL21050064 | 0.83 | CA12 (0.47) | SMN1; SMN2LCKFYNCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327419-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2024-10-03 | — | — | US | claimed |
| EP-4373823-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2024-05-29 | — | — | EP | claimed |
| CN-115181054-B | Synthesis method of 3-benzyl indole compound | 合肥工业大学 | 2024-04-05 | — | — | CN | claimed |
| CN-117730082-A | Synthesis of substituted tricyclic amides and analogs thereof | 爱彼特生物制药公司 | 2024-03-19 | — | — | CN | claimed |
| CN-116396159-A | Synthesis method of 2,2' -biphenyl dicarboxylic acid compound | 湖南大学 | 2023-07-07 | — | — | CN | claimed |
| WO-2023002323-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-26 | — | — | WO | claimed |
| CN-115181054-A | Synthetic method of 3-benzyl indole compound | 合肥工业大学 | 2022-10-14 | — | — | CN | claimed |
| WO-2021257669-A1 | SYNTHESIS OF SUBSTITUTED ARYLMETHYLUREAS, ANALOGUES, AND CRYSTALLINE FORMS THEREOF AND METHODS OF USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-12-23 | — | — | WO | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| EP-4734979-A2 | TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250381179-A1 | CHROMAN-BASED COMPOUNDS FOR TREATING CANCER | ACCUTAR BIOTECHNOLOGY INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| EP-0342849-A2 | Intermediates for preparing 1,4-dihydro-4-oxo-quinoline-3-carboxylic acid esters | PFIZER INC. (US) | 1989-11-23 | — | — | EP | disclosed |
| EP-0303291-A2 | Fluorinated benzoyl compounds | ASAHI GLASS COMPANY LTD. (JP) | 1989-02-15 | — | — | EP | disclosed |
| US-4786649-A | ANTISEPTICS | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-11-22 | — | — | US | disclosed |
| US-4684648-A | Antimicrobial 1-substituted phenyl-4-oxoquinoline-3-carboxylic acid compounds and compositions thereof | OTSUKA PHARMACEUTICAL COMPANY LIMITED (JP) | 1987-08-04 | — | — | US | disclosed |
| EP-0228035-A2 | Antimicrobial 1-thienyl-4-oxoquinoline-3-carboxylix acid compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0181521-A1 | Antimicrobial 1-substituted Phenyl-4-oxoquinoline-3-carboxylic acid compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327419-A1 | SYNTHESIS OF SUBSTITUTED TRICYCLIC AMIDES AND ANALOGUES THEREOF | HCCS, HDGF, GLS2 | SMN1; SMN2 4698/4885LCK 2479/4885FYN 4422/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | SMN1; SMN2 3182/4885LCK 934/4885FYN 3193/4885 |
| US-20250381179-A1 | CHROMAN-BASED COMPOUNDS FOR TREATING CANCER | BRCA1, CDYL, TP53 | SMN1; SMN2 1797/4885LCK 434/4885FYN 868/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | SMN1; SMN2 521/4885LCK 872/4885FYN 1447/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | SMN1; SMN2 286/4885LCK 3693/4885FYN 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.